Last reviewed · How we verify
Transdermal Methylphenidate
Transdermal methylphenidate is a central nervous system stimulant that increases dopamine and norepinephrine availability in the brain by inhibiting their reuptake.
Transdermal methylphenidate is a central nervous system stimulant that increases dopamine and norepinephrine availability in the brain by inhibiting their reuptake. Used for Attention-deficit/hyperactivity disorder (ADHD), Narcolepsy.
At a glance
| Generic name | Transdermal Methylphenidate |
|---|---|
| Also known as | Daytrana |
| Sponsor | St. Louis University |
| Drug class | Sympathomimetic amine; central nervous system stimulant |
| Target | Dopamine transporter (DAT); norepinephrine transporter (NET) |
| Modality | Small molecule |
| Therapeutic area | Neurology; Psychiatry |
| Phase | FDA-approved |
Mechanism of action
Methylphenidate blocks the reuptake of dopamine and norepinephrine at the presynaptic neuron, leading to increased concentrations of these neurotransmitters in the synaptic cleft. The transdermal formulation delivers the drug through the skin, providing sustained release over 9 hours and avoiding first-pass hepatic metabolism. This mechanism enhances attention, focus, and wakefulness, making it effective for attention-deficit/hyperactivity disorder and narcolepsy.
Approved indications
- Attention-deficit/hyperactivity disorder (ADHD)
- Narcolepsy
Common side effects
- Application site reactions (erythema, pruritus)
- Insomnia
- Decreased appetite
- Headache
- Tachycardia
- Anxiety
- Abdominal pain
Key clinical trials
- Exploring the Use of Transdermal Methylphenidate to Reduce Fall Risk in Patients With Dementia. (PHASE4)
- Evaluate the Safety and Efficacy of Methylphenidate Transdermal System (MTS) in Adolescents Aged 13-17 Years With ADHD (PHASE3)
- Characterization of Dermal Reactions in Pediatric Patients With ADHD Using DAYTRANA (PHASE4)
- Evaluate the Efficacy &Safety of Methylphenidate Transdermal System (MTS) in Adolescents Aged 13-17 Years With ADHD (PHASE3)
- Safety and Tolerability of SPD485 in Children Aged 6-12 Diagnosed With ADHD and Previously Participated in MTS Trials (PHASE3)
- Safety & Tolerability of MTS in Children Aged 6-12 Diagnosed With ADHD & Previously Treated With Extended-Release Methylphenidate Therapy (PHASE3)
- Efficacy, Safety and Tolerability of SPD485 in Children Aged 6-12 Diagnosed With ADHD (PHASE2)
- Classroom Study to Assess Efficacy and Safety of MTS in Pediatric Patients Aged 6-12 With ADHD (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |